
Metabolic dysfunction-associated steatotic liver disease (MASLD) remains largely underdiagnosed and asymptomatic, creating major opportunities for pharmacists to drive early identification, lifestyle intervention, and metabolic risk management.

Metabolic dysfunction-associated steatotic liver disease (MASLD) remains largely underdiagnosed and asymptomatic, creating major opportunities for pharmacists to drive early identification, lifestyle intervention, and metabolic risk management.

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 1.3 billion people globally, driven by metabolic disease trends, highlighting urgent needs for earlier detection, prevention, and pharmacist-led intervention.